Literature DB >> 26246677

Optimizing the Care of Patients With Type 2 Diabetes Using Incretin-Based Therapy: Focus on GLP-1 Receptor Agonists.

Mansur Shomali.   

Abstract

Entities:  

Year:  2014        PMID： 26246677      PMCID： PMC4521427          DOI： 10.2337/diaclin.32.1.32

Source DB:  PubMed          Journal:  Clin Diabetes        ISSN： 0891-8929


× No keyword cloud information.
  90 in total

1.  Standards of medical care in diabetes--2013.

Authors: 
Journal:  Diabetes Care       Date:  2013-01       Impact factor: 19.112

2.  2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.

Authors:  Baptist Gallwitz; Julio Rosenstock; Thomas Rauch; Sudipta Bhattacharya; Sanjay Patel; Maximilian von Eynatten; Klaus A Dugi; Hans-Juergen Woerle
Journal:  Lancet       Date:  2012-06-28       Impact factor: 79.321

3.  Effect of problem-solving-based diabetes self-management training on diabetes control in a low income patient sample.

Authors:  Felicia Hill-Briggs; Mariana Lazo; Mark Peyrot; Angela Doswell; Yi-Ting Chang; Martha N Hill; David Levine; Nae-Yuh Wang; Frederick L Brancati
Journal:  J Gen Intern Med       Date:  2011-03-29       Impact factor: 5.128

4.  Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.

Authors:  John B Buse; Michael Nauck; Thomas Forst; Wayne H-H Sheu; Sylvia K Shenouda; Cory R Heilmann; Byron J Hoogwerf; Aijun Gao; Marilyn K Boardman; Mark Fineman; Lisa Porter; Guntram Schernthaner
Journal:  Lancet       Date:  2012-11-07       Impact factor: 79.321

Review 5.  Optimizing outcomes for GLP-1 agonists.

Authors:  Jeffrey S Freeman
Journal:  J Am Osteopath Assoc       Date:  2011-02

6.  A study of patient clues and physician responses in primary care and surgical settings.

Authors:  W Levinson; R Gorawara-Bhat; J Lamb
Journal:  JAMA       Date:  2000 Aug 23-30       Impact factor: 56.272

7.  DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.

Authors:  John B Buse; Daniel J Drucker; Kristin L Taylor; Terri Kim; Brandon Walsh; Hao Hu; Ken Wilhelm; Michael Trautmann; Larry Z Shen; Lisa E Porter
Journal:  Diabetes Care       Date:  2010-03-09       Impact factor: 19.112

Review 8.  How to implement incretin therapy.

Authors:  Michael E Cobble
Journal:  J Fam Pract       Date:  2008-09       Impact factor: 0.493

9.  Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications.

Authors:  Jeffrey R Unger; Christopher G Parkin
Journal:  Diabetes Ther       Date:  2011-01-18       Impact factor: 2.945

10.  Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus.

Authors:  Michael Cobble
Journal:  Diabetol Metab Syndr       Date:  2012-03-05       Impact factor: 3.320
View more
  1 in total

Review 1.  Safety of Semaglutide.

Authors:  Mark M Smits; Daniël H Van Raalte
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-07       Impact factor: 5.555
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.